ViroPharma Stock Rating Lowered by Ned Davis Research (VPHM)
ViroPharma (NASDAQ:VPHM) was downgraded by equities research analysts at Ned Davis Research from a “neutral” rating to a “sell” rating in a research note issued to investors on Monday, AnalystRatingsNetwork reports.
Shares of ViroPharma (NASDAQ:VPHM) traded up 0.23% during mid-day trading on Monday, hitting $39.25. The stock had a trading volume of 109,918 shares. ViroPharma has a 52 week low of $22.12 and a 52 week high of $40.89. The stock’s 50-day moving average is $33.27 and its 200-day moving average is $29.01. The company’s market cap is $2.572 billion.
ViroPharma (NASDAQ:VPHM) last released its earnings data on Thursday, August 1st. The company reported $0.15 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter last year, the company posted ($0.06) earnings per share. ViroPharma’s revenue was up 9.6% compared to the same quarter last year. Analysts expect that ViroPharma will post $-0.78 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank downgraded shares of ViroPharma (NASDAQ:VPHM) from a “buy” rating to a “hold” rating in a research note to investors on Thursday, September 19th. They now have a $43.00 price target on the stock, up previously from $38.00. Separately, analysts at Merrill Lynch downgraded shares of ViroPharma (NASDAQ:VPHM) from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, September 18th. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of ViroPharma (NASDAQ:VPHM) from $27.00 to $30.00 in a research note to investors on Wednesday, September 18th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $37.63.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.